The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
Chimeric Antigen Receptor (CAR) T-Cell Therapy market is currently driven by factors such as the rising incidence of cancer, a strong drug pipeline, rising number of healthcare settings that administer CAR T, improving safety and efficacy of current and emerging therapies, etc. CAR T-cell therapies have a potential to transform cancer treatment by using the immune system to fight diseases. CAR T therapy requires genetically engineering T cells (either a patient’s own or a donor’s) to express a chimeric antigen receptor that targets a particular tumor antigen.
The biggest factor catalyzing the growth of the market is the strong efficacy of these treatment. For instance, pediatric and young adult patients with relapsed or refractory Acute Lymphoblastic Leukemia (ALL) achieved an overall remission rate of 90 percent during the first 12 months with treatment with an anti-CD19 autologous CAR T therapy. However, in spite of, the convincing efficacy data in clinical trials, there are a number of challenges impacting the commercialization of CAR Ts. These challenges include complex and costly manufacturing and supply chain, lengthy and logistically challenging patient journey, and reimbursement challenges. The (CAR) T-Cell Therapy market is set to be a transformative therapy in cancer care, but unleashing its potential will require placing strategic bets. Technological advances and manufacturing innovations are rapidly improving - with the prospects for CAR T to not only treat niche liquid tumors but a broader range of solid and liquid tumors in the near future. Market players that are able to make intelligent investments can significantly expand the number of patients they treat as well as the success rates of their therapies.
IMARC Group’s new report "Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Chimeric Antigen Receptor (CAR) T-Cell Therapy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of current and future landscape of the Chimeric Antigen Receptor (CAR) T-Cell Therapy market. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Chimeric Antigen Receptor (CAR) T-Cell Therapy across the seven major markets. According to the report the United States has the largest patient pool for Chimeric Antigen Receptor (CAR) T-Cell Therapy and also represents the largest market for Chimeric Antigen Receptor (CAR) T-Cell Therapy treatments. Furthermore, the current Chimeric Antigen Receptor (CAR) T-Cell Therapy treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Chimeric Antigen Receptor (CAR) T-Cell Therapy market in any manner.
Time Period of the Study
This report also provides a detailed analysis of the current Chimeric Antigen Receptor (CAR) T-Cell Therapy marketed drugs and late-stage pipeline drugs.
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at